Healthcare Quality and Safety
Healthcare Quality and Safety
News Article | May 3, 2017
BETHLEHEM, Pa., May 03, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will sponsor three educational programs at the Infusion Nurses Society (INS) Spring 2017 Conference that focus on a critical step to peripheral vascular access success, as well as hazardous drug safety. The INS conference is being held May 6-8 at the Minneapolis Convention Center in Minnesota. In collaboration with Christie Medical Holdings, Inc., B. Braun will present two events directed at improving peripheral vascular access through optimal site assessment. Christie and B. Braun recently announced an alliance, whereby B. Braun will sell the Christie VeinViewer® to hospitals in the United States. VeinViewer technology complements B. Braun’s infusion therapy product line by addressing the first step in peripheral IV therapy success by helping the clinician select the best vein for placing an IV catheter. “As a leader in infusion therapy, we are committed to facilitating the sharing of knowledge between healthcare professionals,” said Tom Sutton, Vice President of Vascular Access Systems at B. Braun. “By collaborating with Christie and offering these programs at INS, our goal is to bring healthcare experts and practitioners together to discuss current issues and advance clinical PIV knowledge that helps to improve outcomes, as well as the quality, efficiency and safety of healthcare delivery.” B. Braun also will sponsor a CNE presentation for the INS Daybreak Symposium from 7 to 7:50 a.m. on Tuesday, May 9, in Ballroom A of the Minneapolis Convention Center. “Ready for USP <800>? The Next Chapter in Hazardous Drug Safety” will be presented by Shawn Becker, MS, BSN, Senior Director of Healthcare Quality and Safety, United States Pharmacopeia (USP). To advance USP <800> awareness and education, B. Braun also will feature the new Readyfor800.com website at the company’s booth (#613). The educational resource provides information that will help prepare clinicians for the new USP <800> guidelines that enhance hazardous drug safety for clinicians and patients. Visitors also will be able to learn about the role of a closed system transfer device (CSTD) and the advantages of B. Braun’s OnGuard® CSTD. Also at booth #613, B. Braun will showcase the pathway and products that can lead to successful peripheral IV therapy, including the Christie VeinViewer (Christie booth #713), Introcan Safety® family of PIV catheters, STEADYCare™ extension set with the Wedge™ catheter stabilizer, Ster-ASSIST™ sterile peripheral IV catheter insertion kit, CARESITE® luer access device, and InVision-Plus CS® needleless connector. *VeinViewer is a registered trademark of Christie Medical Holdings, Inc. Christie is the manufacturer and B. Braun is a distributor of VeinViewer. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Etchegaray J.M.,University of Houston |
Ottosen M.J.,Healthcare Quality and Safety |
Burress L.,University of Texas Medical School |
Sage W.M.,University of Texas at Austin |
And 3 more authors.
Health Affairs | Year: 2014
The study of adverse event disclosure has typically focused on the words that are said to the patient and family members after an event. But there is also growing interest in determining how patients and their families can be involved in the analysis of the adverse events that harmed them.We conducted a two-phase study to understand whether patients and families who have experienced an adverse event should be involved in the postevent analysis following the disclosure of a medical error. We first conducted twenty-eight interviews with patients, family members, clinicians, and administrators to determine the extent to which patients and family members are included in event analysis processes and to learn how their experiences might be improved. Then we reviewed our interview findings with patients and health care experts at a one-day national conference in October 2011. After evaluating the findings, conference participants concluded that increasing the involvement of patients and their families in the event analysis process was desirable but needed to be structured in a patient-centered way to be successful. We conclude by describing when and how information from patients might be incorporated into the event analysis process and by offering recommendations on how this might be accomplished. © 2014 Project HOPE-The People-to-People Health Foundation, Inc.